• Skip to main content
  • Skip to primary sidebar

Sporevia probiotic can reduce staph colonization by more than 95%, study finds

Asia Food Journal
  • Home
  • Latest News
  • Channels
    • Packaging
    • Processing
    • Ingredients
    • Industry
    • Automation
    • Guest Posts
    • Market Trends
  • Subscribe
  • Advertise
  • Event Calendar
  • Contact Us
    • Submit Guest Posts
Share
Leaderboard of Asia Food Journal




Sporevia probiotic can reduce staph colonization by more than 95%, study finds

April 10, 2023 by Asia Food Journal

Sporevia probiotic

A female doctor sits at a table with her colleagues as they conduct a meeting. The doctors are all dressed in scrubs and sitting around inventively listening. The doctor to the right is talking with them about her concerns. Courtesy of Kerry Group

Kerry Group’s probiotic strain Sporevia (Bacillus subtilis MB40) can eliminate Staphylococcus aureus in the human body by more than 95 percent, a clinical trial has found.

Staphylococcus aureus (S. aureus), commonly known as “staph,” is a pathogen that caused over 119,000 infections and nearly 20,000 deaths in the US in 2017.1 ​ ​ However, the use of oral antibiotics for staph decolonization is advised against because of its effect on the gut microbiota and antibiotic resistance.2

Leaderboard of Asia Food Journal

Sporevia (Bacillus subtilis MB40) is a probiotic strain owned by Kerry Group following the licensing agreement with BIO-CAT Microbials in June 2021.

The double-blind, randomized, placebo-controlled trial was conducted following the discovery that Sporevia secretes fengycin, which has been shown to inhibit S. aureus colonization.

One hundred and fifteen adults from Thailand took part in the study, which was funded by the US National Institutes of Health and the National Research Council of Thailand. All were colonized by S. aureus, either in the intestine, nose, or both, but had no history of intestinal disease, antibiotic treatment, or hospital admission within the previous 90 days.2

They received either 250 mg of Sporevia* (10 billion CFU) or placebo once a day for 30 days, after which S. aureus colonization was determined. Oral supplementation with Sporevia resulted in a 96.8 percent reduction of S. aureus in the stool and a 65.4 percent reduction of S. aureus in the nose, whereas there were no significant differences in the placebo groups.

Furthermore, these levels of decolonization were achieved without adverse effects or significant microbiome changes. According to the researchers, the findings indicate a potential for Bacillus subtilis to lower infection rates in vulnerable individuals and in long-term care facilities such as nursing homes.

“We were delighted to have Sporevia selected for this study,” says John Menton, PhD, Senior Product Director, Digestive Health, at Kerry Group. “We have long understood the power of spore-forming probiotics to produce metabolites, enzymes and, depending on the strain, fengycins which may inhibit the growth of deleterious bacteria. In this case the study found that Sporevia produces higher amounts of fengycins than other probiotic strains considered for the study, which made it a great candidate for further research. While we’re not surprised by the conclusions, it’s always great to see hypotheses based on in vitro and animal model data supported by clinical trial results. This study is very encouraging as it demonstrates Sporevia’s potential in bacteria management.”

View the full study at: https://www.thelancet.com/action/showPdf?pii=S2666-5247%2822%2900322-6

* The B. subtilis probiotic formula (Sporevia) was purchased from Kerry Group, but the suppliers did not have any influence on the study design or interpretation.

Find out more about the Kerry ProActive Health portfolio here.

References

1 https://www.cdc.gov/media/releases/2019/p0305-deadly-staph-infections.html

2 Piewngam, P., Khongthong, S., Roekngam, N., Theapparat, Y., Sunpaweravong, S., Faroongsarng, D., & Otto, M. (2023). Probiotic for pathogen-specific Staphylococcus aureus decolonisation in Thailand: a phase 2, double-blind, randomised, placebo-controlled trial. The Lancet. Microbe, 4(2), e75–e83.

About Kerry Group 

Kerry is a world leader in taste and nutrition for the food, beverage, and pharmaceutical markets. We innovate with our customers to create great-tasting products with improved nutrition and functionality while ensuring better impact on the planet. Our leading consumer insights, global RD&A team of 1,100+ food scientists, and extensive global footprint enable us to solve our customers’ complex challenges with differentiated solutions. At Kerry, we are driven to be our customers’ most valued partner, creating a world of sustainable nutrition, and will reach over two billion consumers with sustainable nutrition solutions by 2030. For more information, visit www.kerry.com. 

Other Topics: clinical study, Ingredients, Kerry, natural ingredients, Probiotics, sporevia

Related Articles

  • Lee Kum Kee at THAIFEX 2025

    Courtesy of Lee Kum Kee

    Lee Kum Kee at THAIFEX 2025: Connecting the world through Asian culinary culture
  • Arla Foods Ingredients and Alchemy Agencies

    Courtesy of Arla Foods Ingredients

    Arla Foods Ingredients and Alchemy Agencies sign new distribution agreement
  • Jens Birgersson

    Courtesy of Brenntag

    Jens Birgersson to become new CEO of Brenntag SE
  • East Africa CEO Forum

    Courtesy of Kerry

    Kerry’s East Africa CEO Forum unites 100 F&B leaders to reshape the industry’s future through insights and innovation
  • eating habits

    Courtesy of Ohly

    The ‘snackification’ of meals: Expert explains how brands can adapt to changing eating habits 
  • soluble coffee facility

    Courtesy of ofi

    ofi opens soluble coffee facility in Brazil, expanding its manufacturing capacity with focus on sustainable innovation
Leaderboard of Asia Food Journal

Primary Sidebar

Stay Connected

Your browser does not support the video tag. Learn More




🔥 Trending News

Blue Bottle Coffee announces opening of first Southeast Asian outlet in LUMINE
Farmlore in Bengaluru is unveiled as the winner of the American Express One to
Syensqo achieves breakthrough in mechanical recycling of PVDC multilayer
Blue Bottle Coffee announces opening of first Southeast Asian outlet in LUMINE

Trending News

Subsribe to Our News Letter

Subscribe To
Our Newsletter


By submitting this form, you consent to receive marketing emails from Asia Food Journal. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email.

© 2025 Harvest Information. All rights reserved. Privacy Policy.

Become an F&B industry insider

Your go-to resource for all the latest trends, innovations, and news about the food and beverage industry!

 

By submitting this form, you consent to receive marketing emails from Asia Food Journal. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email.

Disclaimer: Translations on this website are automated using Google Translate. While we strive for accuracy, please be cautious, as machine translations may contain errors. For critical or sensitive content, consider seeking professional human translation. We are not liable for any reliance on the translated content.